新型抗癌药物开发的化学研究-猫眼课题宝

新型抗癌药物开发的化学研究

批准号：

3896308

负责人：

J S DRISCOLL

金额：

$0.0万

依托单位：

DIVISION OF CANCER TREATMENT

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/3896308

关键词：

antineoplastics antiviral agents aziridines cell differentiation cyclopentane cytosine analog cytosine arabinoside disease /disorder model drug adverse effect drug design /synthesis /production drug metabolism drug screening /evaluation enzyme inhibitors hydantoins laboratory mouse

项目摘要

项目成果

J S DRISCOLL的其他基金

相似基金

相关文献

中文摘要

翻译

本实验室合成的一种药物Ara-AC已开始临床应用

英文摘要

Ara-AC, a drug synthesized in this laboratory, has begun clinical trials in three institutions. Cyclopentenyl cytosine (CPE-C) has excellent preclinical activity against NCI in vivo tumor models as well as viruses in vitro. CPE-C is active against the standard L1210 leukemia tumor in mice and produces "cures" in the ara-C-resistant L1210 model. It also shows excellent activity against solid human tumor xenograft models (A549 lung, MX-1 mammary, metastatic LOX melanoma) in athymic mice. The compound has outstanding antiviral activity against DNA viruses (HSV-1 (TK+ and TK-), HSV-2, vaccinia, cytomegalovirus, varicella- zoster) and RNA viruses (influenza A2, vesicular stomatitis virus, Japanese encephalitis, Punta Toro, Rift Valley Fever) although, in several instances the antiviral therapeutic indices are low. Based on its antitumor activity, CPE-C has been selected as a potential clinical candidate by the DTP Decision Network Committee.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文